Eyevensys Wins ANSM Approval for Clinical Development of Its EyeCET Platform
French device manufacturer, Eyevensys, has received approval from the French product security regulatory agency (ANSM) to advance its technology into clinical development.
The EyeCET platform uses the company’s electro-transfection injection system to deliver plasmids that encode for the production of disease-specific therapeutic proteins in the ciliary muscle of the eye.
The company’s lead product, EYS606, uses a plasmid encoding for the production of anti-TNFα for the treatment of non-infectious uveitis.
EYS606 has been granted an orphan drug designation by the EMA for the treatment of NIU. — Cynthia Jessup